National Pension Service raised its position in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) by 7.3% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 185,972 shares of the company's stock after acquiring an additional 12,647 shares during the quarter. National Pension Service owned about 0.23% of IDEXX Laboratories worth $93,957,000 as of its most recent SEC filing.
Other institutional investors have also bought and sold shares of the company. Nordea Investment Management AB boosted its position in IDEXX Laboratories by 15.5% during the first quarter. Nordea Investment Management AB now owns 13,719 shares of the company's stock valued at $7,447,000 after acquiring an additional 1,839 shares during the last quarter. Manning & Napier Advisors LLC bought a new stake in IDEXX Laboratories during the second quarter valued at $20,418,000. Oppenheimer Asset Management Inc. boosted its position in IDEXX Laboratories by 13.8% during the second quarter. Oppenheimer Asset Management Inc. now owns 11,957 shares of the company's stock valued at $5,825,000 after acquiring an additional 1,453 shares during the last quarter. Vanguard Group Inc. boosted its position in IDEXX Laboratories by 1.2% during the first quarter. Vanguard Group Inc. now owns 8,476,054 shares of the company's stock valued at $4,576,476,000 after acquiring an additional 98,387 shares during the last quarter. Finally, EFG Asset Management Americas Corp. boosted its position in IDEXX Laboratories by 45.3% during the second quarter. EFG Asset Management Americas Corp. now owns 12,728 shares of the company's stock valued at $6,201,000 after acquiring an additional 3,966 shares during the last quarter. Institutional investors own 87.84% of the company's stock.
IDXX opened at $415.98 on Wednesday. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.42 and a quick ratio of 1.03. The firm has a market capitalization of $34.24 billion, a PE ratio of 40.11, a P/E/G ratio of 3.64 and a beta of 1.36. IDEXX Laboratories, Inc. has a fifty-two week low of $404.74 and a fifty-two week high of $583.39. The company's 50-day moving average is $476.04 and its 200 day moving average is $486.32.
IDEXX Laboratories (NASDAQ:IDXX - Get Free Report) last posted its quarterly earnings data on Thursday, October 31st. The company reported $2.80 EPS for the quarter, beating the consensus estimate of $2.69 by $0.11. The firm had revenue of $975.50 million during the quarter, compared to analyst estimates of $980.32 million. IDEXX Laboratories had a net margin of 22.53% and a return on equity of 55.42%. The company's revenue for the quarter was up 6.6% on a year-over-year basis. During the same quarter last year, the business posted $2.53 EPS. As a group, research analysts predict that IDEXX Laboratories, Inc. will post 10.45 earnings per share for the current fiscal year.
A number of research firms have recently issued reports on IDXX. StockNews.com cut shares of IDEXX Laboratories from a "buy" rating to a "hold" rating in a research report on Wednesday, July 10th. Barclays cut their price objective on shares of IDEXX Laboratories from $570.00 to $481.00 and set an "overweight" rating on the stock in a research report on Monday. BTIG Research began coverage on shares of IDEXX Laboratories in a research report on Thursday, July 25th. They set a "buy" rating and a $580.00 price objective on the stock. Stifel Nicolaus cut their price objective on shares of IDEXX Laboratories from $510.00 to $500.00 and set a "hold" rating on the stock in a research report on Thursday, October 10th. Finally, Piper Sandler reissued a "neutral" rating and set a $435.00 price objective (down previously from $520.00) on shares of IDEXX Laboratories in a research report on Monday. Three investment analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. According to data from MarketBeat, the company currently has an average rating of "Moderate Buy" and an average price target of $552.38.
View Our Latest Report on IDXX
IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
Before you consider IDEXX Laboratories, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and IDEXX Laboratories wasn't on the list.
While IDEXX Laboratories currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.